The decrease was primarily due to lower non-cash losses on impairment related to the Company's identifiable intangible assets, goodwill, and certain investments and convertible note receivable.
As of March 31, 2024, the Company had cash and cash equivalents of approximately $5.0 million and total current liabilities of approximately $2.9 million.
"After reviewing Portage's funding requirements, which necessitated discontinuing the clinical development of its iNKT program and pausing patient enrollment in the ADPORT-601 clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor), we continue to explore strategic alternatives. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions," said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage.
減少は、会社の識別可能な無形資産、商標、特定の投資および転換可能なノート債権に関連する非現金損失が低くなったためです。
2024年3月31日時点で、同社はおよそ500万ドルの現金及び現金同等物を保有し、総流動負債はおよそ290万ドルです。
「ポーテージの資金調達要件を検討した結果、iNKtプログラムの臨床開発を中止し、PORt-6(アデノシン2A阻害剤)およびPORt-7(アデノシン2B阻害剤)のADPORt-601臨床試験の患者登録を一時停止する必要がありました。今後も、1つ以上の資産に対するパートナーの探索、当社の売却、合併、(裁判所内外の)再編成、会社の閉鎖、さらなる資金調達の努力、あるいはその他の戦略的措置等を含む戦略的な代替案を模索していきます」と、ポーテージの最高経営責任者兼会長のIan Walters博士は述べています。